The phrase “SCLC transformation” is increasingly being used in clinical literature, especially for patients diagnosed with EGFR mutation-positive NSCLC after receiving EGFR tyrosine kinase inhibitor (TKI) therapy [15,16]. Here, EGFR is linked to small cell lung carcinoma.